Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Pharma channel feed
After abruptly pulling its marketing application, DBV may be left with peanuts in race against Aimmune
7 years ago
R&D
FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment
7 years ago
Gilead dangles $105M in quick cash to sign Scholar Rock to a discovery deal for its growing NASH pipeline
7 years ago
R&D
With cancer in focus, Amgen taps Molecular Partners' preclinical immune-oncology asset for $50M upfront
7 years ago
Ready to consummate its Shire buyout, Takeda plans US dual listing while NYSE loses a major pharma to Nasdaq
7 years ago
Reimagining medicine? Novartis wraps pharma’s first big global pot deal
7 years ago
Sanofi is concentrating its forces in Cambridge hub, inking a massive lease for 2,700 staffers
7 years ago
FibroGen, AstraZeneca score China approval for anemia drug ahead of pivotal US data
7 years ago
China
FDA names new No. 2 to replace retiring Sherman
7 years ago
Junshi wins the race for first made-in-China PD-1 approval as execs reap $394M IPO harvest
7 years ago
Financing
China
Novo Nordisk grabs a $486M buyout option on an anti-apoC3 antibody for its cardio R&D group
7 years ago
Deals
Tossed in a storm of controversies, Proteostasis finds shelter in $100M cash Roche deal — shares surge
7 years ago
Broadening its oncology focus, Innovent adds three Incyte drugs to portfolio for $40M cash
7 years ago
R&D
China
Eli Lilly has anted up for its next big bet on a next-gen pain drug, buying Hydra assets
7 years ago
Anatomy of a long-delayed biotech buyout: With its stock price beaten down, abandoned by potential bidders, Tesaro wound up in GSK’s eager arms
7 years ago
Plowing ahead after its latest setback, Axovant nabs two assets to beef up gene therapy pipeline
7 years ago
R&D
Under pressure, drugmakers dilute price hikes, but nothing is set in stone just yet — report
7 years ago
Two years and $78M later, Amgen washes its hands of Advaxis' I/O drug — and shares plummet
7 years ago
This is the FDA’s year to shine, but can biopharma keep up as regulators continue to rev up chart-topping numbers?
7 years ago
Mylan claims win in Lantus patent battle, but legal war with Sanofi is far from over
7 years ago
Who needs venture backers? Bill Haney bags new deal cash from Celgene as his biotech upstart Dragonfly explores NK cell tech
7 years ago
Another one of Bob Langer's MIT postdocs scores a biotech deal, auctioning his startup for up to $415M
7 years ago
Bausch is keen on Synergy, after troubled constipation drug maker files for Chapter 11
7 years ago
FDA rolls out expectations for a looming regulatory shift for insulin and other biologics
7 years ago
First page
Previous page
280
281
282
283
284
285
286
Next page
Last page